|
"hsu ta"的相關文件
顯示項目 6-15 / 92 (共10頁)
1 2 3 4 5 6 7 8 9 10 > >>
每頁顯示[10|25|50]項目
| 國家衛生研究院 |
2022-06-21 |
Synthesis and evaluation of small molecule drug conjugates harnessing thioester-linked maytansinoids
|
Lo, CF;Chiu, TY;Liu, YT;Huang, LR;Yeh, TK;Huang, KH;Liu, KL;Hsu, CY;Fang, MY;Huang, YC;Hsu, TA;Chen, CT;Tsou, LK |
| 國家衛生研究院 |
2022-02-07 |
Development of furanopyrimidine-based orally active third-generation EGFR inhibitors for the treatment of non-small cell lung cancer
|
Li, MC;Coumar, MS;Lin, SY;Lin, YS;Huang, GL;Chen, CH;Lien, TW;Wu, YW;Chen, YT;Chen, CP;Huang, YC;Yeh, KC;Yang, CM;Kalita, B;Pan, SL;Hsu, TA;Yeh, TK;Chen, CT;Hsieh, HP |
| 國家衛生研究院 |
2022-01-18 |
Acyl-coenzyme a synthetase long-chain family member 4 is involved in viral replication organelle formation and facilitates virus replication via ferroptosis
|
Kung, YA;Chiang, HJ;Li, ML;Gong, YN;Chiu, HP;Hung, CT;Huang, PN;Huang, SY;Wang, PY;Hsu, TA;Brewer, G;Shih, SR |
| 國家衛生研究院 |
2021-08-10 |
Anti-Abeta antibodies and uses thereof
|
Shie, FS;Hsu, TA;Shih, C;Shen, ST |
| 國家衛生研究院 |
2021-07-16 |
Colloidal assemblies composed of polymeric micellar/emulsified systems integrate cancer therapy combining a tumor-associated antigen vaccine and chemotherapeutic regimens
|
Huang, CY;Lin, SY;Hsu, TA;Hsieh, HP;Huang, MH |
| 國家衛生研究院 |
2020-05-23 |
Repurposing old drugs as antiviral agents for coronaviruses
|
Yang, CW;Peng, TT;Hsu, HY;Lee, YZ;Wu, SH;Lin, WH;Ke, YY;Hsu, TA;Yeh, TK;Huang, WZ;Lin, JH;Sytwu, HK;Chen, CT;Lee, SJ |
| 國家衛生研究院 |
2020-05-15 |
Artificial intelligence approach fighting COVID-19 with repurposing drugs
|
Ke, YY;Peng, TT;Yeh, TK;Huang, WZ;Chang, SE;Wu, SH;Hung, HC;Hsu, TA;Lee, SJ;Song, JS;Lin, WH;Chiang, TJ;Lin, JH;Sytwu, HK;Chen, CT |
| 國家衛生研究院 |
2019-12-17 |
Endothelial-mesenchymal transition harnesses HSP90alpha-secreting M2-macrophages to exacerbate pancreatic ductal adenocarcinoma
|
Fan, CS;Chen, LL;Hsu, TA;Chen, CC;Chua, KV;Li, CP;Huang, TS |
| 國家衛生研究院 |
2019-10 |
Discovery of clinical candidate DBPR112, a furanopyrimidine-based epidermal growth factor receptor inhibitor for the treatment of non-small cell lung cancer
|
Hsieh, HP;Chang, JY;Yeh, CT;Lin, SY;Ke, YY;Lin, WH;Hsu, TA;Wu, SY;Yeh, TK |
| 國家衛生研究院 |
2019-09-27 |
Discovery of a furanopyrimidine-based epidermal growth factor receptor inhibitor (DBPR112) as a clinical candidate for the treatment of non-small cell lung cancer
|
Lin, SY;Chang Hsu, Y;Peng, YH;Ke, YY;Lin, WH;Sun, HY;Shiao, HY;Kuo, FM;Chen, PY;Lien, TW;Chen, CH;Chu, CY;Wang, SY;Yeh, KC;Chen, CP;Hsu, TA;Wu, SY;Yeh, TK;Chen, CT;Hsieh, HP |
顯示項目 6-15 / 92 (共10頁)
1 2 3 4 5 6 7 8 9 10 > >>
每頁顯示[10|25|50]項目
|
